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Abstract Elevated homocysteine concentrations are
associated with a decline in physical function in elderly
persons. Homocysteine-lowering therapy may slow down
this decline. This study aimed to examine the effect of a
2-year intervention of vitamin B12 and folic acid supple-
mentation on physical performance, handgrip strength, and
risk of falling in elderly subjects in a double-blind, ran-
domized placebo-controlled trial. Participants aged
C65 years with elevated plasma homocysteine concentra-
tions [12–50 lmol/L (n = 2919)] were randomly assigned
to daily supplementation of 500 lg vitamin B12, 400 lg
folic acid, and 600 IU vitamin D3, or to placebo with
600 IU vitamin D3. Physical performance (range 0–12)
and handgrip strength (kg) were measured at baseline and
after 2 years. Falls were reported prospectively on a
research calendar. Intention-to-treat (primary) and per-
protocol (secondary) analyses were performed. Physical
performance level and handgrip strength significantly
decreased during the follow-up period, but this decline did
not differ between groups. Moreover, time to first fall was
not significantly different (HR: 1.0, 95 % CI 0.9–1.2).
Secondary analyses on a per-protocol base identified an
interaction effect with age on physical performance. In
addition, the treatment was associated with higher follow-
up scores on the walking test (cumulative OR: 1.3, 95 % CI
1.1–1.5). Two-year supplementation of vitamin B12 and
folic acid was neither effective in reducing the age-related
decline in physical performance and handgrip strength, nor
in the prevention of falling in elderly persons. Despite the
overall null-effect, the results provide indications for a
positive effect of the intervention on gait, as well as on
physical performance among compliant persons[80 years.
These effects should be further tested in future studies.
Keywords Homocysteine  Aging  Falling  Physical
function  Vitamin B12  Folic acid
Introduction
Poor physical function in the elderly is associated with
adverse health outcomes, including falls and fractures, a
reduced quality of life, nursing home admission and mor-
tality [1–5]. Circulating homocysteine (Hcy) concentra-
tions increase with age, and elevated concentrations occur
in up to 50 % of persons over the age of 60 [6]. Elevated
Hcy levels have been identified as independent risk factor
for fractures [7, 8]. In addition, Hcy has been suggested to
have effects on multiple systems, including vascular and
neuromuscular systems, and these systems may affect
mobility and gait. Reduction in muscle strength, physical
& Karin M. A. Swart
k.swart@vumc.nl
1 Department of Epidemiology and Biostatistics and the
EMGO Institute for Health and Care Research, VU
University Medical Center, Van der Boechorststraat 7,
1081 BT Amsterdam, The Netherlands
2 Department of Internal Medicine, Erasmus MC,
P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
3 Department of Human Nutrition, Wageningen University,
P.O. Box 8129, 6700 EV Wageningen, The Netherlands
4 Department of Internal Medicine, Endocrine Section and the
EMGO Institute for Health and Care Research, VU
University Medical Center, P.O. Box 7057,
1007 MB Amsterdam, The Netherlands
123
Calcif Tissue Int (2016) 98:18–27
DOI 10.1007/s00223-015-0059-5
performance, and falling may be an intermediate pathway
by which high Hcy induces an increased fracture risk in
older persons. In the past decade, the association between
Hcy and physical function has been examined in several
cross-sectional and longitudinal observational studies.
These studies have consistently shown that elevated Hcy
concentrations are associated with accelerated decline in
mobility and muscle strength [9–15]. Hcy-induced neuro-
logical deterioration or adverse muscle characteristics are
thought to account for the observed associations [16, 17].
Elevated Hcy concentrations can effectively be reduced
with vitamin B12 and/or folic acid supplementation [18]. If
the relation between Hcy and physical function is causal,
supplementation can be expected to prevent or slow down
decline in physical function in the elderly, and this should
be tested in randomized controlled trials. One such inter-
vention study investigated the effect of randomly assigned
B-vitamin supplementation versus placebo on movement
performance in a population of elderly [19], and did not
demonstrate a difference. However, participants were only
followed for 4 months, which might be too short for
physical decline to occur. A second intervention study
reported no difference in fall rate after 2 years of vitamin
B12 and folic acid supplementation versus placebo in a
highly selective population of stroke survivors [20].
The aim of the current study was to investigate the effect
of a 2-year intervention of daily vitamin B12 and folic acid
supplementation on changes in physical performance,
handgrip strength, and the risk of falling in a mildly
hyperhomocysteinemic elderly population.
Subjects and Methods
Design and Study Sample
The B-vitamins in the prevention of osteoporotic fractures
(B-PROOF) study is a double-blind, randomized, placebo-
controlled trial. The main outcome of the trial was the
incidence of osteoporotic fractures; physical performance,
handgrip strength, and falls were pre-specified secondary
outcomes. The study design of the B-PROOF study has
been published elsewhere [21]. In short, the intervention
comprised daily oral supplementation of 500 lg vitamin
B12, 400 lg folic acid, and 600 IU vitamin D for a period
of 2 years. The placebo tablet contained 600 IU vitamin D
only. Vitamin D was added to ensure normal vitamin D
concentrations. The tablets were indistinguishable with
respect to smell, taste, and appearance. The random allo-
cation sequence was computer-generated. Randomization
was carried out by an independent research dietician to a
one-by-one allocation ratio in blocks of 24, after stratifi-
cation for sex, age (65–80, C80 years), study location, and
baseline Hcy concentration (12–18 lmol, C18 lmol). Both
the participants and the research team, including examiners
and data-analyzers, were blinded for the treatment alloca-
tion. Persons were included if they were aged C65 years,
and had plasma Hcy concentration of 12–50 lmol/L. Per-
sons were excluded if they had a history of cancer in the
last 5 years, except non-melanoma skin cancer, if they
were bedridden or wheelchair bound, had a serum crea-
tinine concentration [150 lmol/L, or if they currently or
recently (\4 months) used supplements with very high
doses of vitamin B12 (intramuscular injections) or folic
acid (300 lg/day). A total of 2919 participants were
included from October 2008 to March 2011. Subsequently,
follow-up was completed in March 2013. Measurements
were performed at baseline and after 2 years by trained
examiners. Furthermore, the participants recorded falls and
fractures prospectively on a research calendar. Persons who
dropped-out during follow-up were asked if they agreed to
continue to complete the calendar and to participate at the
2-year follow-up measurements.
The B-PROOF study was carried out by a consortium of
researchers from Wageningen University (WU), VU
University Medical Center (VUmc), and Erasmus MC, the
Netherlands. The B-PROOF study was approved by the
Medical Ethics Committee of WU, and the Medical Ethics
Committees of VUmc and Erasmus MC gave additional
approval for local feasibility. All participants gave written
informed consent. B-RPOOF is registered with the
Netherlands Trial Register (NTR1333), and the Clini-
calTrials.gov (NCT 00696514).
Outcomes
Physical performance was assessed with three function
tests. During the walking test, the time needed to walk
three meters back and forth as quickly as possible was
measured. The chair stands contained the measurement of
the time needed to stand up from and sit down on a chair
for five successive times, without using hands. During the
tandem stand, the ability to stand with the feet right in front
of each other for 10 s with eyes open was measured. Scores
on the walking test (0–4) and the chair stands (0–4) were
based on timed quartiles of the study sample [14]. The
tandem stand was categorized as follows: unable or able to
hold position less than 4 s (score 0), able to hold position
for 4–9 s (score 2), able to hold position for at least 10 s
(score 4). Total physical performance score was calculated
by summing up the scores of the three individual compo-
nents, and consequently ranged from zero (low physical
performance) to twelve (high physical performance). These
physical performance tests have been used in the Longi-
tudinal Aging Study Amsterdam and a lower score have
been associated with adverse outcomes, such as functional
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decline and institutionalization [22], an increased fracture
risk [4], and depression [23] in older persons.
Handgrip strength (kg) was measured with a hand held
dynamometer (Takei TKK 5401, Takei Scientific Instru-
ments CO. Ltd., Tokyo, Japan). Two maximum handgrip
strength trials were performed with each hand. Handgrip
strength was calculated as the mean of the highest scores of
both hands.
Falling was assessed prospectively during the study
period. Participants reported falls weekly on the research
calendar. Calendar pages were returned to the study centers
every 3 months. Participants were contacted if calendars
were incomplete or unclear. Drop-outs with no further
calendar information after drop-out were assigned as lost-
to-follow-up. Time to first and time to second fall were
regarded as outcomes as well as the number of falls per
individual.
Compliance
Participants returned their remaining supplement tablets bi-
annually. Compliance was assessed by count of the
returned tablets. Two different definitions of compliance
were used. First, concerning physical performance and
handgrip strength, compliance was defined as taking at
least 80 % of the tablets in the 2-year period between
baseline and follow-up. Second, concerning time to falling,
80 % was used as cutoff for compliance for the time the
participant actually participated (i.e., time to study com-
pletion, or time to drop-out).
Baseline Characteristics
Plasma Hcy, serum holotranscobalamin, methylmalonic
acid, vitamin B12, and folate were determined. Details of
the determination were described previously [21]. To
assure the quality of the Hcy measurement during the
inclusion period of the study, Hcy was measured in series,
and control samples were analyzed during all series.
Smoking habits (former, current, no smoker), alcohol use
(light, moderate, excessive), physical activity, education
level (low, intermediate, high), B12 and/or folic acid sup-
plement use, and retrospective falling were assessed with
questionnaires. Standing height was measured using a
stadiometer, and weight using a calibrated scale (Seca,
Deventer, the Netherlands). Cardiovascular disease was
self-reported and was defined as the presence of arrhyth-
mia, angina pectoris, myocardial infarction, heart fail-
ure/valve dysfunction, arterial septum defect, pericarditis,
aneurysm, or pulmonal hypertension. Global cognitive
functioning was measured with the Mini Mental State
Examination.
Statistical Analyses
For physical performance, a decline of 0.6 points is
expected in 2 years in the placebo group (adapted from
[15]), and we expect this decline to be prevented in the
intervention group. Based on this expected difference of
0.6 between the treatment groups, a standard deviation of
3.2 and a power of 80 % to detect this difference, 448
participants per group would be needed. Similarly, a
decline in handgrip strength of 2.3 kg is expected in
2 years in the placebo group (adapted from [13]), and we
expect this decline to be prevented in the intervention
group. With a power of 80 %, and standard deviation of
10.0, 298 participants in both groups are needed.
Analyses were performed using IBM SPSS Statistics 20
(IBM, Armonk, New York, United States). Comparisons of
baseline characteristics between treatment groups have
been made previously [24]. Additional baseline compar-
isons between the intervention and placebo group were
made using a t test for physical performance and handgrip
strength, using a v2 test for percentage of retrospective
fallers and the presence of cardiovascular disease, and
using a Mann–Whitney U test for cognitive functioning.
The primary analyses were performed according to the
intention-to-treat (ITT) principle, in which all participants
were included. With respect to physical performance and
handgrip strength, linear mixed model analyses were per-
formed to assess the effect of the treatment. An important
feature of this model, necessary for longitudinal analyses,
is that the dependency of repeated observations within
subjects is taken into account. Moreover, all subjects with
at least one observation are included, regardless of missing
values. Thus, subjects with baseline data who were lost to
follow-up were also included in the analyses. The treatment
effect is the mean difference from baseline to follow-up in
the treatment group compared with the mean difference
from baseline to follow-up in the placebo group, as defined
by the treatment-by-time interaction.
With respect to falling, differences in time to first and
time to second fall between treatment groups were tested
with the crude log-rank test. Moreover, Cox proportional
hazards analyses were performed to assess the HR of
falling. Person-time was the time to first/second fall, time
to lost-to-follow-up, or time to study completion, which-
ever came first. The assumptions of proportional hazards
were assessed by visual judgment of the log-minus-log
survival plots, and were not violated. To compare the
number of falls per participant across treatment groups
while allowing for multiple events, we used the negative
binomial model.
Crude analyses were performed, and analyses adjusted
for age, sex, study center, baseline Hcy, and variables that
differed between groups at baseline, i.e., baseline
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holotranscobalamin. The analyses of the number of falls
were additionally adjusted for participation time, i.e., time
to lost-to-follow-up, or time to study completion. Interac-
tion of age (below and above 80 years), sex, and baseline
Hcy concentration (below and above 18 lmol/L) with the
treatment effect were studied, and in addition the interac-
tion with baseline physical performance (below and above
two points), baseline handgrip strength (below and above
16 kg), or B12 and/or folic acid supplement use was tested
in post hoc analyses. A p value of B0.10 for interaction was
considered as a justification for stratified analyses.
In secondary analyses, the association between change
in Hcy (instead of treatment allocation) and the outcomes
was studied using regression analyses. In addition, ordinal
logistic regression was used to examine the association
between the treatment and the individual performance tests
(walking test, chair stands and tandem stand). Assumptions
of ordinal logistic regression were tested by the test of the
parallel lines and were fulfilled if the two lowest categories
were combined.
The main analyses were repeated according to the per-
protocol (PP) principle, in which only compliant partici-
pants were included. Significance level of the effect was set
at p\ 0.05.
Results
Of the 2919 included participants, 1461 were assigned to
the intervention group, and 1458 to the placebo group. The
drop-out rate was 14.5 %. Among the drop-outs, 144 par-
ticipants (34 %) agreed to complete the follow-up mea-
surements, and 84 drop-outs (20 %) still completed the
research calendar (Fig. 1). Baseline comparisons between
the intervention and placebo group are presented in
Table 1. Data on 2-year changes in Hcy, folate, holo-
transcobalamin, vitamin B12, and methylmalonic acid have
been published previously [25].
A significant 2-year decline in physical performance
score was observed in both the intervention (p\ 0.01) and
placebo group (p\ 0.01). Linear mixed models did not
show a significant treatment effect, indicating that the
decline did not differ between treatment groups (treatment
effect: 0.1; 95 % CI -0.1–0.3) (Table 2). No interactions
with age, sex, and baseline Hcy concentration were
observed. In addition, the post hoc interaction with baseline
physical performance or B12 and/or folic acid supplement
use was not significant.
The PP analyses, with 84 % of the participants included,
showed similar results (Table 2). In the PP analyses, evi-
dence for interaction with age was observed (p = 0.10).
Stratified analyses showed that in persons B80 years
(n = 2107) the decline in physical performance score was
not significantly different between treatment groups
(treatment effect: 0.0; 95 % CI -0.2–0.3). In persons
[80 years (n = 340), a treatment effect of 0.6 was
observed (95 % CI 0.0–1.1), which was close to statistical
significance (Fig. 2). Results were similar after adjustments
for age, sex, study center, baseline Hcy, and baseline
holotranscobalamin (data not shown).
Secondary analyses revealed that the 2-year change in
Hcy (median: -2.4 lmol/L, IQR: -4.7 to 0.1 lmol/L) was
significantly associated with follow-up physical perfor-
mance scores (B: -0.03; 95 % CI -0.05 to -0.01). When
testing the association between the treatment and the
individual physical performance tests, the cumulative OR
for the walking test was 1.3 (95 % CI 1.1–1.5), indicating
that persons in the placebo group were 1.3 times more
likely to score 1 point lower on the walking test, as com-
pared with persons in the treatment group. For the chair
stands and the tandem stand the cumulative ORs were 1.0
(95 % CI 0.8–1.1) and 0.9 (95 % CI 0.7–1.1), respectively.
Regarding handgrip strength, a significant 2-year decline
in both treatment groups was observed (p\ 0.01 for both
groups). The decline was not significantly different
between groups (treatment effect: 0.1; 95 % CI -0.2–0.4)
(Table 2). No interaction effects were observed. PP results
were similar (Table 2), and also adjustments for con-
founders did not change the findings (data not shown). Also
the 2-year change in Hcy was not associated with follow-
up handgrip strength (B: -0.01; 95 % CI -0.05–0.02).
Total follow-up time for falling was 2914.7 person-years
in the intervention group and 2940.7 person-years in the
placebo group. In the intervention group, 1747 falls
occurred in 683 fallers (fall rate: 59.9/100 person-years)
versus 1663 falls in 681 fallers (fall rate: 56.6/100 person-
years) in the placebo group. Both time to the first fall and
time to the second fall were not significantly different
between the intervention and placebo group (log rank
p = 0.63 and p = 0.23, respectively) (Fig. 3 for time to
first fall). Also, Cox proportional hazards models did not
show statistically significant differences between treatment
groups with respect to time to first fall (HR: 1.0; 95 % CI
0.9–1.2) and time to second fall (HR: 1.1; 95 % CI
0.9–1.3). For time to first fall, a significant interaction was
observed with Hcy concentration (p = 0.05), but stratified
analyses did not show significant effects in persons with
Hcy B18 or [18 lmol/L (data not shown). In addition,
negative binomial regression showed that the intervention
had no significant effect on the number of falls per par-
ticipant (OR: 1.0; 95 % CI 0.9–1.1). Similar results were
observed in the PP analyses, and after adjustment for
confounders (data not shown). The 2-year change in Hcy
was not associated with falling (HR:1.0; 95 % CI 1.0–1.0).
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Discussion
Two-year daily supplementation of vitamin B12 and folic
acid in hyperhomocysteinemic persons[65 years was not
effective in reducing the age-related decline in physical
performance and handgrip strength. In addition, the inter-
vention had no effect on the risk of falling. Despite the
overall null-effect, the results provide indications for a
positive effect of the intervention on walking as component
of physical performance, as well as on physical perfor-
mance among compliant persons[80 years.
This is the first study performed in a large sample of
elderly, with moderate long-term follow-up duration.
Although a higher decrease in Hcy was associated with
higher follow-up performance scores, this effect was rather
small and cannot be considered clinically relevant. The
overall results are in line with previous findings of Lewerin
et al. [19]. In that study, movement performance as indi-
cated by a postural-locomotor-manual test did not improve
after 4 months of treatment with 0.5 mg vitamin B12,
0.8 mg folic acid, and 3 mg vitamin B6 versus placebo in
elderly participants (n = 209, mean age: 76 years (range
70–93 years), mean Hcy: 17.2 lmol/L). However, inter-
action effects with age were not examined in that study. In
the randomized controlled trial of Sato et al., no differences
in fall incidence between the intervention and placebo
Randomizaon and 
start intervenon       
N=2,919
Intervenon group  
N=1,461
Baseline data on
- Physical performance N=1,441
- Handgrip strength N=1,442
Placebo group  
N=1,458
Baseline data on
- Physical performance N=1,434
- Handgrip strength N=1,446
Drop-out N=222
-  Deceased N=16
-  No longer movated or 
personal event N=42
-  No longer capable, too 
burdensome N=118
-  Perceived side effects N=14
-  Reason unknown N=32
…………………………………………
-  Agreed follow-up 
measurement N=82
-  Agreed to connue fall 
calendar N=47
Drop-out N=200
-  Deceased N=26
-  No longer movated or 
personal event N=40
-  No longer capable, too 
burdensome N=92
-  Perceived side effects N=13
-  Reason unknown N=29
…………………………………………
-  Agreed follow-up 
measurement N=62
-  Agreed to connue fall 
calendar N=37
Follow-up data on 
-  Physical performance N=1,266
-  Handgrip strength N=1,304
-  Falling N=1,461
Follow-up data on
-  Physical performance N=1,280 
-  Handgrip strength N=1,309
-  Falling N=1,458
Included in the intenon-to-treat 
analyses                           
-  Physical performance  
 N=1,454*
-  Handgrip strength N=1,453*
-  Falling N=1,461
* With data on baseline and/or  
 follow-up
Included in the intenon-to-
treat analyses 
-  Physical performance  
 N=1,452*
-  Handgrip strength N=1,455*
-  Falling N=1,458
* With data on baseline and/or  
 follow-up
Fig. 1 Flow chart of the
B-PROOF study sample
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group were reported after 2-year supplementation of
1.5 mg vitamin B12 and 5 mg folic acid among a highly
selective sample of stroke survivors (n = 628, mean Hcy:
19.9 lmol/L) [20]. Those findings are consistent with our
results too.
Secondary analyses indicated that the intervention might
have a positive effect on walking performance, in contrast
to chair stands and tandem stand. The walking test includes
aspects of coordination, proximal muscle strength, and
balance, whereas the chair stands and the tandem stands
only include aspect of proximal muscle strength and bal-
ance, respectively. Previously, it has been shown in
observational data that high Hcy levels are most strongly
associated with the walking test and the chair stands [15].
The current findings are partly in line with those previous
observations.
Table 1 Baseline
characteristics of the 2919
participants of the B-PROOF
study according to treatment
group
Placebo group
N = 1458
Intervention group
N = 1461
p value
Age (years)a 74.0 ± 6.6 74.2 ± 6.4 0.60
Sex (% women)b 50.4 49.7 0.71
Homocysteine (lmol/L)c 14.3 (13.0–16.5) 14.5 (13.0–16.7) 0.46
Holotranscobalamin (pmol/L)c 63.0 (45.0–84.0) 65.0 (48.0–86.0) 0.03*
Methylmalonic acid (lmol/L)c 0.23 (0.18–0.31) 0.22 (0.18–0.30) 0.25
Vitamin B12 (pmol/L)c 266 (204–343) 267 (213–341) 0.27
Folate (nmol/L)c 18.9 (14.8–24.5) 18.8 (14.9–24.7) 0.50
Creatinine (lmol/L)a 84.1 ± 18.0 83.9 ± 18.6 0.73
Height (cm)a 169.2 ± 9.3 169.4 ± 9.4 0.63
Weight (kg)a 77.8 ± 13.3 77.9 ± 13.3 0.99
Current smoker (%)b 9.7 9.5 0.97
Alcohol useb 0.46
Light (%) 66.8 68.0
Moderate (%) 29.0 28.5
Excessive (%) 4.2 3.5
Physical activity (min/day)c 131 (86–193) 126 (81–190) 0.17
Educationb 0.79
Low (%) 53.6 52.4
Intermediate (%) 21.1 21.1
High (%) 25.4 26.5
B12 and/or folic acid supplement use (% yes)b 15.8 15.3 0.76
Vitamin D supplement use (% yes)b 19.7 18.3 0.64
Retrospective falls (% yes)b 32.6 32.5 0.96
Physical performance (0–12)c 8.1 ± 3.2 8.0 ± 3.1 0.37
Walking test 3 (2–4) 3 (2–4) 0.08
Chair stands 3 (2–4) 3 (2–4) 0.39
Tandem stand 4 (0–4) 4 (0–4) 0.43
Handgrip strength (kg)a 31.0 ± 10.6 30.8 ± 10.6 0.71
Study centerb 0.91
WU (%) 29.2 29.6
VUmc (%) 26.4 26.8
Erasmus MC (%) 44.4 43.6
Cardiovascular disease (% yes) 25.0 24.1 0.46
MMSE score 28 (27–29) 28 (27–29) 0.10
VUmc VU University Medical Center, WU Wageningen University, MMSE mini-mental state examination
* p\ 0.05
a Presented as mean ± SD, difference tested using t test
b Presented as percentages, differences tested using v2 test
c Presented as median (IQR), differences tested using Mann–Whitney U test
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In a subgroup of persons[80 years who were compliant
in taking the supplement, a tendency toward a preventive
effect on decline in physical performance was observed.
The number of persons per treatment group in this analysis
was relatively small (162 in the intervention and 178 in the
placebo group). Although the results were not statistically
significant, they might be clinically relevant. Previous
studies showed that a change in the Short Physical Per-
formance Battery (SPPB) (which also consists of a walk-
ing, chair stands and balance test) of 0.3–0.8 points may be
considered as minimally clinically relevant among the
elderly, and a change of 0.4–1.5 points as substantially
clinically relevant [26, 27]. The currently used perfor-
mance tests use different components than the SPPB, i.e.,
6 m maximal walking speed vs 4 m habitual speed, and a
different scoring of the balance test. However, it is similar
with respect to the scorings range (0–12), and therefore the
identified relevant change might be helpful in providing
some indication of what can be considered as relevant
change in our study. We believe that our observed change
of 0.6 points might be even more relevant for persons
[80 years as compared to persons B80 years, since base-
line physical performance scores in this subgroup were
significantly lower as compared to persons B80 years.
Because the interaction effect with age was only observed
in secondary analyses on a PP base, the subgroup effect on
physical performance can be considered as a hypothesis
that needs to be tested in further studies.
Recently, we have shown that B-vitamin supplementa-
tion was effective in the prevention of fractures in com-
pliant persons [80 years [24]. This is in line with the
observed borderline effect on physical performance in
compliant persons [80 years in the current paper. The
mechanism of action by which supplementation reduces
the fracture risk remains uncertain. It has been suggested
that bone mineral density, collagen cross-linking, osteo-
clast activity, and/or methylation capacity may be involved
[28]. An alternative or complementary intermediate might
be physical function. To test this hypothesis, we added
physical performance scores to the fracture analyses in a
post hoc analysis. In the compliant 80? subgroup with data
on physical performance, the HR for fractures in the
intervention group was 0.3 and did not change after
adjustment for physical performance scores. This indicates
that physical performance cannot be considered as a
mediator in the reported effect on fractures.
With respect to handgrip strength, we observed a
decrease of 1.3 kg in the intervention group whereas in the
placebo group a decrease of 1.4 kg was observed. A recent
study with data from four intervention trials aimed at
improving strength and physical function among post-
menopausal women demonstrated that those with handgrip
weakness at baseline had a better response to the inter-
ventions [29]. Such an interaction effect was not observed
Table 2 The effect of the intervention on physical performance and handgrip strength, as derived from linear mixed models
Intervention group Placebo group Treatment
effecta (95 % CI)
SE p value
Baseline
estimated
mean
Follow-up
estimated
mean
2-Year
change
Baseline
estimated
mean
Follow-up
estimated
mean
2-year
change
Physical performance score
Intention-to-treat 8.0 7.6 -0.4 8.1 7.6 -0.5 0.1 (-0.1 to 0.3) 0.10 0.36
Per-protocol 8.3 7.9 -0.4 8.3 7.9 -0.5 0.1 (-0.1 to 0.3) 0.10 0.33
Handgrip strength (kg)
Intention-to-treat 30.9 29.6 -1.3 30.9 29.5 -1.4 0.1 (-0.2 to 0.4) 0.14 0.48
Per-protocol 31.7 30.5 -1.3 31.7 30.2 -1.5 0.2 (-0.1 to 0.5) 0.15 0.15
CI confidence interval, SE standard error
a The treatment effect is the mean difference from baseline to follow-up in the intervention group compared with the mean difference from
baseline to follow-up in the placebo group, as determined by the treatment-by-time estimate
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Fig. 2 Two-year decline in physical performance scores according to
treatment group among participants[80 years, as derived from linear
mixed models (per-protocol analysis)
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for lower extremity strength, indicating that the upper body
may be more adaptable to interventions in older adults.
Although handgrip strength is correlated with lower
extremity strength or overall strength, it cannot replace the
assessment of lower extremity strength [30]. In our study,
indications for a greater treatment effect among those with
handgrip weakness were not found, as the interaction of
treatment effect with baseline handgrip strength was not
significant.
Both the intervention and placebo tablets contained
600 IU vitamin D. In a meta-analysis of 13 studies, positive
effects of vitamin D supplementation on muscle function
have been demonstrated among elderly persons [31].
Another meta-analysis observed a reduced fall risk and rate
of falls with vitamin D supplementation among the elderly
[32]. Vitamin D receptors have been located in many tissues,
such as muscle tissue and brain tissue [33, 34]. Age-related
decline in vitamin D concentration and reduction of activity
and expression of vitamin D receptors have been associated
with reduced muscle cell function and are suggested to affect
neuromuscular control and coordination [35, 36]. The pres-
ence of vitamin D supplementation in both treatment arms
has most likely reduced the contrast between the groups and
may have attenuated the results, although vitamin D and
vitamin B12/folic acid supplementation are assumed not to
have similar mechanistic actions.
Another limitation might be that the participants in the
current study were only mildly hyperhomocysteinemic, with
a few vitamin B12 (4 %) or folate (3 %) deficient partici-
pants, which may have diminished the effect of supplemen-
tation. In addition, the results might have been attenuated by
the inclusion of participants that already used vitamin B12
and/or folic acid supplements (16 %), although we did not
observe an interaction effect of B12 and/or folic acid sup-
plement use. While we only observed an interaction effect of
baseline Hcy with treatment for the outcome falling, with no
significant effects in subsequent stratified analyses, the
results might be different in case of severe hyperhomocys-
teinemia. In general, because the participants were screened
for Hcy levels and Hcy levels have been linked to several
adverse health outcomes (cardiovascular disease, cognitive
decline, osteoporosis), the B-PROOF sample might be less
healthy than the general population of older persons. On the
other hand, persons who are willing to participate in nutri-
tion-related randomized controlled trials are in general more
healthy. The strength of this study is its randomized con-
trolled study design, as well as the large number of included
participants. In addition, the compliance to the treatment was
good; the randomization resulted in two very well balanced
groups; and the applied doses of vitamin B12 and folic acid
were sufficient to lower Hcy levels [24]. It should be noted
that more cancer diagnoses were observed in the intervention
group as compared to placebo, as reported previously [24].
In conclusion, this study showed no overall effect of daily
2-year supplementation of vitamin B12 and folic acid on
physical performance, handgrip strength, and falling among
elderly persons with mild hyperhomocysteinemia. A ten-
dency toward a positive effect on physical performance
among compliant persons[80 years, as well as on gait was
observed. As the loss of mobility in older persons forms an
increasing public health issue in the context of rapidly
expanding older populations, the current findings are
important for advancing future research on preserving
mobility in older persons. The current results emphasize the
need for trials among the oldest old and on lower extremity
functioning.
Fig. 3 Kaplan-Meier plot of the
first fall according to treatment
group (intention-to-treat).
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